A multicenter trial suggested that baminercept significantly reduced the plasma levels of CXCL13 and altered the number of circulating B and T cells in SS patients, but failed to significantly improve glandular and extra-glandular disease in SS patients (127). The gene discussed is CXCL13; the disease is synovial sarcoma.